Zumbach K, Kisseljov F, Sacharova O, Shaichaev G, Semjonova L, Pavlova L, Pawlita M
Angewandte Tumorvirologie, Deutsches Krebsforschungszentrum, Heidelberg, Germany.
Int J Cancer. 2000 Feb 1;85(3):313-8. doi: 10.1002/(sici)1097-0215(20000201)85:3<313::aid-ijc3>3.0.co;2-w.
Certain human papillomaviruses (HPV), mainly types 16 and 18, have been widely recognized as an essential etiologic factor for the development of carcinoma of the uterine cervix. The early HPV proteins E6 and E7 are consistently expressed in the tumor cells, and cervical-carcinoma patients can develop antibodies against these oncoproteins. For cervical-carcinoma patients from Eastern Europe and Russia, detailed information on HPV DNA prevalence and HPV-specific immune responses is limited. The presence of HPV DNA in 128 Russian cervical-carcinoma tissues was determined: HPV16 DNA was found in 78% of the cases, HPV18 DNA in 14%, and no HPV-DNA in 10%. Using 4 recently developed sensitive and highly specific second-generation enzyme-linked immunosorbent assays, we also analyzed the prevalence of antibodies against HPV16 and -18 E6 and E7 proteins in sera from 95 cervical-carcinoma patients, from 61 female patients with non-HPV-associated tumors and from 83 female healthy controls. The strong association of E6 and/or E7 antibodies with cervical carcinoma was confirmed, with 36% seropositives in this group against only 2% in the control groups. The detected antibodies are highly HPV-type-specific since all 26 HPV16-E6- or -E7-antibody-positive patients had HPV16 DNA in their tumor and 6 out of the 8 HPV18-antibody-positive patients had HPV18 DNA. Antibody responses to HPV16 E6 and E7 appear to be dependent on clinical stage of the disease, with 21% seropositives found in FIGO stage I, 42% in stage II and 53% in stage III. Antibody response to HPV16 E6 is more frequent than to E7, especially in early stages.
某些人乳头瘤病毒（HPV），主要是16型和18型，已被广泛认为是子宫颈癌发生的重要病因。HPV早期蛋白E6和E7在肿瘤细胞中持续表达，宫颈癌患者可产生针对这些癌蛋白的抗体。对于来自东欧和俄罗斯的宫颈癌患者，关于HPV DNA流行率和HPV特异性免疫反应的详细信息有限。我们测定了128份俄罗斯宫颈癌组织中的HPV DNA：78%的病例中发现了HPV16 DNA，14%中发现了HPV18 DNA，10%中未发现HPV DNA。我们还使用4种最新开发的灵敏且高度特异的第二代酶联免疫吸附试验，分析了95例宫颈癌患者、61例非HPV相关肿瘤女性患者和83例健康女性对照血清中针对HPV16和18 E6和E7蛋白抗体的流行情况。E6和/或E7抗体与宫颈癌的强关联得到证实，该组中36%为血清阳性，而对照组中仅为2%。检测到的抗体具有高度的HPV型特异性，因为所有26例HPV16 - E6或 - E7抗体阳性患者的肿瘤中都有HPV16 DNA，8例HPV18抗体阳性患者中有6例有HPV18 DNA。对HPV16 E6和E7的抗体反应似乎取决于疾病的临床分期，在国际妇产科联盟（FIGO）I期患者中21%为血清阳性，II期为42%，III期为53%。对HPV16 E6的抗体反应比对E7更常见，尤其是在早期阶段。
